AP23573: Phase I data

In 2 open-label, U.S. Phase I trials, 49% of the

Read the full 107 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE